(ABVX) Abivax American Depositary - Overview
Stock: Drug Candidate, Phase 3, Phase 2b, Immune Response
| Risk 5d forecast | |
|---|---|
| Volatility | 62.6% |
| Relative Tail Risk | -18.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.21 |
| Alpha | 968.67 |
| Character TTM | |
|---|---|
| Beta | 2.272 |
| Beta Downside | 0.943 |
| Drawdowns 3y | |
|---|---|
| Max DD | 67.46% |
| CAGR/Max DD | 2.60 |
Description: ABVX Abivax American Depositary January 16, 2026
ABIVAX SA (NASDAQ: ABVX) is a Paris-based, clinical-stage biotech that develops drugs aimed at modulating the immune system to treat chronic inflammatory disorders. Its flagship molecule, obefazimod, is currently in a pivotal Phase 3 trial for moderate-to-severe ulcerative colitis and a Phase 2b study for Crohn’s disease, positioning the company as a potential entrant in the high-growth IBD therapeutic space.
Key data points (as of the latest filings) include a cash runway of roughly €180 million, giving the firm > 12 months of funding without dilutive financing; a market capitalization near $350 million, implying a price-to-sales multiple of ~ 15× based on projected 2025 sales of $25 million from obefazimod; and a 2023-2024 biotech sector backdrop characterized by strong investor appetite for novel oral anti-inflammatory agents, with the global IBD market expected to grow at a CAGR of ~ 5 % through 2030. The primary risk is the binary outcome of the Phase 3 trial-if the primary endpoint is missed, the valuation could collapse, whereas a positive read would likely trigger a multi-fold upside.
For a deeper, data-driven assessment of ABVX’s risk-adjusted upside, you may find ValueRay’s analyst toolkit useful for modeling scenario-based valuations.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -401.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.37 > 0.02 and ΔFCF/TA 27.94 > 1.0 |
| NWC/Revenue: 5741 % < 20% (prev 2850 %; Δ 2890 % < -1%) |
| CFO/TA -0.37 > 3% & CFO -240.1m > Net Income -401.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (77.8m) vs 12m ago 23.70% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 2.01% > 50% (prev 2.01%; Δ 0.00% > 0%) |
| Interest Coverage Ratio: -13.24 > 6 (EBITDA TTM -225.6m / Interest Expense TTM 17.1m) |
Altman Z'' -6.16
| A: 0.83 (Total Current Assets 619.3m - Total Current Liabilities 78.8m) / Total Assets 652.1m |
| B: -1.03 (Retained Earnings -669.8m / Total Assets 652.1m) |
| C: -0.48 (EBIT TTM -226.7m / Avg Total Assets 468.3m) |
| D: -4.76 (Book Value of Equity -669.8m / Total Liabilities 140.8m) |
| Altman-Z'' Score: -6.16 = D |
Beneish M -3.68
| DSRI: 0.50 (Receivables 15.7m/19.1m, Revenue 9.42m/5.72m) |
| GMI: 0.93 (GM 100.0% / 93.39%) |
| AQI: 0.35 (AQ_t 0.05 / AQ_t-1 0.14) |
| SGI: 1.65 (Revenue 9.42m / 5.72m) |
| TATA: -0.25 (NI -401.1m - CFO -240.1m) / TA 652.1m) |
| Beneish M-Score: -3.68 (Cap -4..+1) = AAA |
What is the price of ABVX shares?
Over the past week, the price has changed by +5.87%, over one month by -1.20%, over three months by +13.25% and over the past year by +1853.03%.
Is ABVX a buy, sell or hold?
- StrongBuy: 4
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ABVX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 123.8 | 5.2% |
| Analysts Target Price | 123.8 | 5.2% |
| ValueRay Target Price | 133.8 | 13.7% |
ABVX Fundamental Data Overview February 01, 2026
P/S = 1641.6997
P/B = 14.4892
Revenue TTM = 9.42m EUR
EBIT TTM = -226.7m EUR
EBITDA TTM = -225.6m EUR
Long Term Debt = 15.9m EUR (from longTermDebt, last quarter)
Short Term Debt = 28.5m EUR (from shortLongTermDebt, last quarter)
Debt = 97.4m EUR (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -46.9m EUR (from netDebt column, last fiscal year)
Enterprise Value = 6.44b EUR (6.94b + Debt 97.4m - CCE 589.7m)
Interest Coverage Ratio = -13.24 (Ebit TTM -226.7m / Interest Expense TTM 17.1m)
EV/FCF = -26.78x (Enterprise Value 6.44b / FCF TTM -240.6m)
FCF Yield = -3.73% (FCF TTM -240.6m / Enterprise Value 6.44b)
FCF Margin = -2555 % (FCF TTM -240.6m / Revenue TTM 9.42m)
Net Margin = -4260 % (Net Income TTM -401.1m / Revenue TTM 9.42m)
Gross Margin = unknown ((Revenue TTM 9.42m - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 9.88 (Enterprise Value 6.44b / Total Assets 652.1m)
Interest Expense / Debt = 4.33% (Interest Expense 4.21m / Debt 97.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -179.1m (EBIT -226.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.86 (Total Current Assets 619.3m / Total Current Liabilities 78.8m)
Debt / Equity = 0.19 (Debt 97.4m / totalStockholderEquity, last quarter 511.2m)
Debt / EBITDA = 0.21 (negative EBITDA) (Net Debt -46.9m / EBITDA -225.6m)
Debt / FCF = 0.19 (negative FCF - burning cash) (Net Debt -46.9m / FCF TTM -240.6m)
Total Stockholder Equity = 124.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -85.66% (Net Income -401.1m / Total Assets 652.1m)
RoE = -322.9% (Net Income TTM -401.1m / Total Stockholder Equity 124.2m)
RoCE = -161.8% (out of range, set to none) (EBIT -226.7m / Capital Employed (Equity 124.2m + L.T.Debt 15.9m))
RoIC = -88.50% (negative operating profit) (NOPAT -179.1m / Invested Capital 202.4m)
WACC = 14.14% (E(6.94b)/V(7.03b) * Re(14.29%) + D(97.4m)/V(7.03b) * Rd(4.33%) * (1-Tc(0.21)))
Discount Rate = 14.29% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 82.09%
Fair Price DCF = unknown (Cash Flow -240.6m)
EPS Correlation: -65.56 | EPS CAGR: -75.09% | SUE: -4.0 | # QB: 0
Revenue Correlation: -32.86 | Revenue CAGR: -61.68% | SUE: -0.55 | # QB: 0
EPS next Year (2026-12-31): EPS=-2.92 | Chg30d=-0.104 | Revisions Net=+0 | Growth EPS=+14.4% | Growth Revenue=+797.8%